SCHEMBL3009740

SCHEMBL3009740

CCOc1ccc(-c2csc(N3CCC(S(=O)(=O)c4cc(Cl)ccc4Cl)CC3)n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.48
LMNA P02545 4/20 0.48
TSHR P16473 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
SMN1; SMN2 Q16637 7/20 0.46
MAPK1 P28482 5/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
RAB9A P51151 7/20 0.44
NPC1 O15118 5/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
ALDH1A1 P00352 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
AR P10275 1/20 0.40
HTT P42858 1/20 0.40
FFAR2 O15552 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013899 0.93 MAPT (0.48) MAPTLMNATSHRNPSR1SMN1; SMN2
SCHEMBL3011336 0.91 RAB9A (0.49) MAPTLMNATSHRNPSR1SMN1; SMN2
SCHEMBL3017087 0.90 SMN1; SMN2 (0.56) MAPTLMNATSHRNPSR1SMN1; SMN2
SCHEMBL3020092 0.89 MAPT (0.48) MAPTLMNATSHRNPSR1SMN1; SMN2
SCHEMBL3012836 0.89 LMNA (0.41) MAPTLMNATSHRNPSR1SMN1; SMN2
SCHEMBL3020335 0.89 SMN1; SMN2 (0.53) MAPTLMNATSHRNPSR1SMN1; SMN2
SCHEMBL3018502 0.89 MAPT (0.46) MAPTLMNATSHRNPSR1SMN1; SMN2
SCHEMBL3016516 0.88 MAPT (0.53) MAPTLMNATSHRNPSR1SMN1; SMN2
SCHEMBL3008132 0.88 SMN1; SMN2 (0.48) MAPTLMNATSHRNPSR1SMN1; SMN2
SCHEMBL3019741 0.87 MAPT (0.54) MAPTLMNATSHRNPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885LMNA 80/4885TSHR 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.